Search clinical trials for: MK-8189

Total 1743 results

Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)

Hepatic Impairment

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)

Bipolar I Disorder
Merck Sharp & Dohme LLC

Completed

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Alzheimer's Disease

United States
Endocyte

Terminated

A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)

Solid Tumor
Merck Sharp & Dohme LLC

Completed

MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)

Schizophrenia, Acute Episode

United States
Merck Sharp & Dohme LLC

Completed

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) (MDCS)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

Schizophrenia

United States, Bulgaria, Croatia, Japan, Korea, Republic of, Latvia, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine
Gilead Sciences

Terminated

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma

United States
Merck Sharp & Dohme LLC

Completed

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019) (TQT)

Schizophrenia

United States
Bristol-Myers Squibb

Completed

A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

Healthy
Endocyte

Terminated

A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)

Advanced Cancer
Neuralstem Inc.

Unknown

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Shandong Suncadia Medicine Co., Ltd.

Recruiting

Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Tumor

China
Bristol-Myers Squibb

Completed

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Healthy | Hepatitis C

United States, Puerto Rico
Kangpu Biopharmaceuticals, Ltd.

Active, not recruiting

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE (Lupus)

SLE; Drug

United States
Neuralstem Inc.

Unknown

Study of NSI-189 for Major Depressive Disorder

Major Depressive Disorder

United States
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Neuralstem Inc.

Completed

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Depression

United States
ModernaTX, Inc.

Active, not recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Epstein-Barr Virus Infection

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Kainos Medicine Inc.
Parexel

Recruiting

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

Multiple System Atrophy

Korea, Republic of
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients

Carcinoma | Advanced Cancer

Taiwan
Kangpu Biopharmaceuticals, Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

Systemic Lupus Erythematosus

United States
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer

Ovarian Cancer

Israel
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms

United States, Israel
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
M.D. Anderson Cancer Center

Recruiting

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Bristol-Myers Squibb

Completed

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects (INH-189-006)

Hepatitis C

United States, Puerto Rico
TaiRx, Inc.

Active, not recruiting

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine Neoplasm

Taiwan
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
FAScinate Therapeutics Inc.
Parexel

Recruiting

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease

Parkinson Disease

United States
TaiRx, Inc.

Completed

A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

Carcinoma | Advanced Cancer

United States
Kainos Medicine Inc.

Completed

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

Parkinson's Disease

Korea, Republic of
Kangpu Biopharmaceuticals, Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Hematological Malignancies

United States
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C

3

Subscribe